甲状腺髓样癌患者术前诊断与否的结局比较:一项多中心回顾性队列研究
这项在以色列开展的多中心回顾性队列研究纳入94例组织学确诊的甲状腺髓样癌(MTC)患者,比较术前确诊组(53例,56%)与仅术后确诊组(41例,44%)的手术范围和结局。术前确诊组更常行全甲状腺切除及中央区、同侧侧颈淋巴结清扫,但两组生化治愈率无显著差异(55% vs 64%,p=0.41);排除微小MTC后术前确诊组生化治愈率更高(33% vs 62%,p=0.04),且总生存更优(log-rank p=0.04)。
要点
- 术前确诊MTC者全甲状腺切除、中央区及侧颈淋巴结清扫比例更高。
- 两组总体生化治愈率无显著差异,排除微小MTC后术前确诊组更优。
- 术前确诊组总生存优于未确诊组(log-rank p=0.04)。
核心结论
- 术前MTC诊断常被遗漏;准确的术前诊断可能使患者接受与指南一致的手术治疗,并最终有助于改善MTC患者的总生存。
研究设计与样本
- 多中心、回顾性、队列研究,纳入2000年1月至2021年6月在以色列治疗的MTC患者,按有无术前MTC诊断分组比较。
主要发现
- 共纳入94例组织学确诊MTC患者,平均年龄56.2±14.3岁,43%为男性;术前确诊组53例(56%),仅术后确诊组41例(44%)。
- 仅术后确诊组 vs 术前确诊组:全甲状腺切除83% vs 100%(p=0.002),中央区淋巴结清扫46% vs 98%(p<0.001),同侧侧颈淋巴结清扫36% vs 79%(p<0.001),对侧侧颈淋巴结清扫17% vs 28%(NS)。
- 仅术后确诊组 vs 术前确诊组:中位肿瘤大小16±17.4 mm vs 23±14.0 mm(p=0.09),微小MTC(≤10 mm)比例32% vs 15%(p=0.03),合并滤泡细胞来源癌比例24% vs 4%(p=0.003)。
- 两组甲状腺外侵犯和结外侵犯率无显著差异;末次随访时生化治愈率仅术后确诊组55%[CI 0.38-0.71] vs 术前确诊组64%[CI 0.50-0.77](p=0.41)。
- 排除微小MTC后,术前确诊组生化治愈更常见(33%[CI 0.14-0.52] vs 62%[CI 0.46-0.77],p=0.04);中位随访82个月(IQR 30-153)期间,术前确诊组总生存优于仅术后确诊组(log-rank p=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Cytological limitations pose a challenge to preoperative diagnosis of medullary thyroid carcinoma (MTC) and therefore, a significant subset of patients is only diagnosed postoperatively. The objective of this study was to investigate the impact of knowledge of a preoperative MTC diagnosis on disease management and outcomes. Methods: Multicenter, retrospective, cohort study of MTC patients treated in Israel from January 2000 to June 2021. We compared cohorts of patients according to the presence or absence of a preoperative MTC diagnosis. Results: Ninety-four patients with histologically confirmed MTC were included (mean age 56.2 ± 14.3 years, 43% males). Fifty-three patients (56%) had a preoperative MTC diagnosis (preop-Dx group), and 41 (44%) were confirmed only postoperatively (no-Dx group). The extent of surgical resection, including completion procedures, was as follows: total thyroidectomy in 83% versus 100% (p = 0.002), central lymph node dissection (LND) in 46% versus 98% (p < 0.001), ipsilateral lateral LND in 36% versus 79% (p < 0.001), and contralateral lateral LND in 17% versus 28% (NS), in the no-Dx versus the preop-Dx group, respectively. Pathology confirmed a smaller median tumor size of 16 ± 17.4 mm versus 23 ± 14.0 mm (p = 0.09), a higher proportion of micro-MTC (size ≤10 mm) 32% versus 15% (p = 0.03), and a higher rate of co-occurrence of follicular cell-derived carcinoma 24% versus 4% (p = 0.003), in the no-Dx compared to the preop-Dx group, respectively. The rates of extrathyroidal and extranodal tumor extension were not significantly different between the groups. At the last follow-up, the biochemical cure was attained in 55% [CI 0.38-0.71] compared to 64% [CI 0.50-0.77] of the no-Dx and the preop-Dx group, respectively (p = 0.41). After the exclusion of patients with micro-MTC, biochemical cure was more commonly achieved in the preop-Dx group (33% [CI 0.14-0.52] vs. 62% [CI 0.46-0.77], p = 0.04). Preop-Dx patients had improved overall survival compared to the no-Dx group (log-rank p = 0.04) over a median follow-up of 82 months (interquartile range [IQR] 30-153). Conclusions: Preoperatively, the diagnosis of MTC is often missed. An accurate preoperative diagnosis of MTC may enable guideline-concordant surgical treatment and ultimately contribute to an overall survival benefit in MTC patients.
引用
- Oleinikov K, Yaakov E, Mizrachi A, et al. A Comparison of Outcomes in Medullary Thyroid Carcinoma Patients With and Without a Preoperative Diagnosis: A Multicenter Retrospective Cohort Study. Thyroid. 2023. PMID: 36792935. doi:10.1089/thy.2022.0424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。